Publicaciones en las que colabora con Aurora Pujol (20)

2022

  1. Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy

    Acta Neuropathologica, Vol. 144, Núm. 2, pp. 241-258

  2. Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model

    Neuropathology and Applied Neurobiology, Vol. 48, Núm. 1

2021

  1. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment

    Neuropathology and Applied Neurobiology, Vol. 47, Núm. 4, pp. 544-563

2019

  1. Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

    Neurotherapeutics, Vol. 16, Núm. 4, pp. 1167-1182

2018

  1. Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

    EMBO Molecular Medicine, Vol. 10, Núm. 8

2017

  1. Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance

    Aging Cell, Vol. 16, Núm. 6, pp. 1404-1413

2016

  1. Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury

    GLIA, Vol. 64, Núm. 5, pp. 853-874

2015

  1. Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy

    Cell Death and Differentiation, Vol. 22, Núm. 11, pp. 1742-1753

  2. Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy

    Human Molecular Genetics, Vol. 24, Núm. 24, pp. 6861-6876

  3. Deregulation of purine metabolism in Alzheimer's disease

    Neurobiology of Aging, Vol. 36, Núm. 1, pp. 68-80

  4. Neuroinflammatory signals in alzheimer disease and APP/PS1 transgenic mice: Correlations with plaques, tangles, and oligomeric species

    Journal of Neuropathology and Experimental Neurology, Vol. 74, Núm. 4, pp. 319-344

2014

  1. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

    Human Molecular Genetics, Vol. 23, Núm. 14, pp. 3716-3732

2013

  1. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

    Human Molecular Genetics, Vol. 22, Núm. 16, pp. 3296-3305

  2. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy

    Brain, Vol. 136, Núm. 8, pp. 2432-2443

2012

  1. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease

    Brain Pathology, Vol. 22, Núm. 5, pp. 636-653

  2. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases?

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1822, Núm. 9, pp. 1475-1488

2011

  1. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy

    Annals of Neurology, Vol. 70, Núm. 1, pp. 84-92

  2. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy

    Antioxidants and Redox Signaling, Vol. 15, Núm. 8, pp. 2095-2107

2010

  1. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy

    Human Molecular Genetics, Vol. 19, Núm. 10, pp. 2005-2014

2008

  1. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy

    Human Molecular Genetics, Vol. 17, Núm. 12, pp. 1762-1773